Role of Checkpoint Inhibition in Localized Bladder Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Role of Checkpoint Inhibition in Localized Bladder Cancer

Published:2018-08 Issue:3 Volume:1 Page:190-198
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Hahn Noah M.,Necchi Andrea,Loriot Yohann,Powles Thomas,Plimack Elizabeth R.,Sonpavde Guru,Roupret Morgan,Kamat Ashish M.

Publisher

Elsevier BV

Subject

Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery

Reference49 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study;Balar;Lancet Oncol,2017

3. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial;Balar;Lancet,2017

4. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

5. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial;Patel;Lancet Oncol,2018

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis;Frontiers in Immunology;2024-01-09

2. Molecular classification of urothelial bladder carcinoma;Molecular Biology Reports;2023-07-31

3. Diagnostic, Therapeutic and Prognostic Implications of Urothelial Carcinoma, A Review;Pakistan Journal of Health Sciences;2023-05-31

4. Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer;Frontiers in Immunology;2022-08-17

5. Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer;Biomedicines;2022-02-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3